IPO Year: 2022
Exchange: NYSE
Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to ac
Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customers and Deliver High-Quality Therapies to Patients Vendors and Suppliers Expected to be Paid in Full in the Ordinary Course DUBLIN, Aug. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of th
Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust Financial Restructuring Plan to Significantly Reduce Debt, Increase Free Cash Flow Generation, Extend Maturity Runway and Better Position Company for Long-Term Success Intends to Initiate Voluntary Prepackaged Chapter 11 Proceedings to Implement Plan Continuing to Deliver High-Quality Therapies to Patients and Serve Customers; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN, Aug. 23, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced it has entered into a Restructur
The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (NYSE:MNK), today issued an open letter (the "Letter") to the Company's Board of Directors, regarding the Company's continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360 and Regulation S-X, within its August 9, 2023, Form 10-Q filing with the U.S. Securities and Exchange Commission (the "Commission"). On March 17, 2023, BHG had issued a public report to the Company's Board of Directors (al
Reports Second Quarter Net Sales of $475.0 Million, Reflecting a 1.3% Growth on a Reported and Constant Currency Basis Compared to the Prior Year Quarter Reports Net Loss of $747.8 Million; Adjusted EBITDA of $144.0 Million; Cash on Hand of $480.6 Million at Second Quarter End Reaffirms 2023 Net Sales and Adjusted EBITDA Guidance Terlivaz® Launch Exceeds Expectations, Obtaining Approximately 50% of Targeted Hospital Formulary Access With Continued Medical Community Interest Provides Update on Liquidity and Discussions With Creditors and Opioid Disbursement Trust DUBLIN, Aug. 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutic
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 13, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSEAM:MNK) investors that a lawsuit filed on behalf of investors that purchased Mallinckrodt securities between June 17, 2022 and June 14, 2023, both dates inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss invest
– Two scientific poster presentations at EASL 2023 will detail findings of Mallinckrodt's latest research providing insight into the therapeutic effect of TERLIVAZ® from baseline, and the clinical management of adults with HRS with rapid reduction in kidney function1 – DUBLIN, June 15, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that two scientific posters detailing Mallinckrodt's latest research findings on the clinical outcomes of treatment with TERLIVAZ® (terlipressin) for injection and clinical management criteria for adult patients with hepatorenal syndrome (HRS) will be presented at the European Association for the Study
– Findings from two clinical studies in adults with HRS involving rapid reduction in kidney function1 provide insight into the use of terlipressin among patients with comorbidities and varying baseline characteristics2,3 – DUBLIN, June 1, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical studies in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 treated with TERLIVAZ® (terlipressin) for injection at the American Transplant Congress (ATC) 2023, taking place in San Diego, Calif. from June 3-7, 2023. The results of the two studies – a pooled analysis of two Ph
The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. ("Mallinckrodt" or the "Company") (NYSE:MNK), today issued an open letter (the "Letter") to the Company's Board of Directors, given the Company's continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360 and Regulation S-X, within its May 9, 2023, Form 10-Q filing with the U.S. Securities and Exchange Commission (the "Commission"). On March 17, 2023, BHG issued a public report to the Company's Board of Directors (also delivere
Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli
4 - Mallinckrodt plc (0001567892) (Issuer)
4 - Mallinckrodt plc (0001567892) (Issuer)
4 - Mallinckrodt plc (0001567892) (Issuer)
4 - Mallinckrodt plc (0001567892) (Issuer)
4 - Mallinckrodt plc (0001567892) (Issuer)
3 - Mallinckrodt plc (0001567892) (Issuer)
Mallinckrodt plc (OTC:MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on August 28, 2023. As expected, the Court granted Mallinckrodt approval to access $150 million of the $250 million of commitments for new financing it received from certain of its creditors, as well as new borrowing availability from lenders under its asset-based loans. The approvals granted by the Court also enable the Company to continue paying employee wages, salaries and benefits without
Reuters Walmart Settles Lawsuit Regarding Allegations Of Light-Bulb Patent Infringement Walmart Inc (NYSE:WMT) has reportedly resolved the University of California's light-bulb patent lawsuit. The university accused the retail behemoth of infringing its patents associated with "filament" LED light bulbs (invented at the Santa Barbara-based school system). The federal judge in Los Angeles would dismiss the case with prejudice, which means it cannot be refiled. Renault Eyes Spring 2024 IPO For EV Unit Ampere Renault SA (OTC:RNLSY) (OTC:RNSDF) is reportedly expecting to list its electric vehicle business unit, Ampere, on the stock market in the spring of 2024. Renault Chief Executiv
Mallinckrodt Plc (NYSE:MNK) has taken the next steps to implement the comprehensive financial restructuring plan. The company and some of its subsidiaries have filed for a second bankruptcy in three years in the U.S., with the newest restructuring plan set to reduce its debt by about $1.9 billion. The company expects to complete the court-supervised process in the fourth quarter of 2023. The RSA also provides for a final, one-time payment of $250 million, among other considerations. In addition to the $450 million the company previously paid, this payment is intended to support the Trust's mission to address the U.S. opioid crisis and fund addiction treatment. The 156-year-old company
The jury seeks information and data relating to the Company’s reporting of suspicious orders for controlled substances, chargebacks, and other transactions, and communications between the Company and the U.S. Drug Enforcement Administration regarding those issues.
Rite Aid Corp (NYSE:RAD) is reportedly on the brink of filing for bankruptcy amidst many lawsuits over its purported role in the opioid crisis to address its significant debt burden, which exceeds $3.3 billion, through a Chapter 11 filing. The drug retailer is grappling with over a thousand consolidated federal lawsuits in Ohio and numerous similar state lawsuits. The Justice Department has slapped Rite Aid with a civil lawsuit, accusing it of dispensing controlled drugs violating the False Claims Act and Controlled Substances Act. Rite Aid's financial health has deteriorated with declining revenues and mounting losses. Furthermore, its shares plummeted by over 80% within a year. This
Gainers Cano Health (NYSE:CANO) shares rose 58.7% to $0.37 during Friday's regular session. As of 13:31 EST, Cano Health's stock is trading at a volume of 98.0 million, which is 1253.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $104.2 million. YS Biopharma Co (NASDAQ:YS) stock increased by 41.19% to $1.1. As of 13:31 EST, this security is trading at a volume of 38.1 million shares, making up 5860.1% of its average full-day volume over the last 100 days. The company's market cap stands at $102.3 million. Aptorum Gr (NASDAQ:APM) stock increased by 34.37% to $2.37. As of 13:31 EST, this security is trading at a volume of 6.2 mil
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares rose 30.2% to $40.05 during Wednesday's regular session. Trading volume for Apellis Pharmaceuticals's stock is 9.9 million as of 13:31 EST. This is 229.8% of its average full-day volume over the last 100 days. The company's market cap stands at $4.7 billion. Aditxt (NASDAQ:ADTX) stock increased by 29.82% to $12.99. Trading volume for Aditxt's stock is 441.2K as of 13:31 EST. This is 745.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.4 million. ITeos Therapeutics (NASDAQ:ITOS) shares moved upwards by 26.63% to $14.88. Trading volume for ITeos Therapeutics's stock is 8.2 mil
8-K - Mallinckrodt plc (0001567892) (Filer)
8-K - Mallinckrodt plc (0001567892) (Filer)
10-Q - Mallinckrodt plc (0001567892) (Filer)
8-K - Mallinckrodt plc (0001567892) (Filer)
8-K - Mallinckrodt plc (0001567892) (Filer)
8-K - Mallinckrodt plc (0001567892) (Filer)
8-K - Mallinckrodt plc (0001567892) (Filer)
10-Q - Mallinckrodt plc (0001567892) (Filer)
DEFA14A - Mallinckrodt plc (0001567892) (Filer)
DEF 14A - Mallinckrodt plc (0001567892) (Filer)
DUBLIN, Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023. With more than 30 years of research and development experience in the pharmaceutical industry, Dr. Richardson will have executive responsibility for Mallinckrodt's branded research and development (R&D), medical affairs, safety, and regulatory affairs functions. He will serve on the Company's Executive Committee and succeeds Steven Romano, M.D., who departed Mallinckrodt in Dece
Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, May 9, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Malli
DUBLIN, April 24, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIbe1f9805fe5b4490acd8359f7bdd616dAudio Only Webcast Link (live and replay):https://edge.media-server.com/mmc/p/24fqexpxAt the Mallinckrodt website
Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executing Clinical Programs and Advancing Product Development Pipelines Increased Cash on Hand to $409.5 Million, Underscoring Commitment to Strengthening Balance Sheet and Disciplined Approach to Cost Management Fiscal 2023 Guidance for Adjusted EBITDA is $510 Million to $560 Million Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Feb. 28, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022.
DUBLIN, Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BI6e1a95af3f634687b3c55b1ae6b4ffd8 Audio Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/mfaw2pmzAt the Mallinckro
Launched Terlivaz® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generation Delivery System of INOmax® Strengthened Organization with Appointment of New Executives and Directors; Ordinary Shares Commenced Trading on NYSE American in October Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN, Nov. 8, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the third quarter ended September 30, 2022.1
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D/A - Mallinckrodt plc (0001567892) (Subject)
SC 13D - Mallinckrodt plc (0001567892) (Subject)